唾液酸转移酶ST6GALNAC1在头颈部鳞状细胞癌中的表达及其预后和免疫学价值

doi:10.3969/j.issn.1009-976X.2023.02.009

摘要/Abstract

摘要： 目的本研究旨在利用生物信息学分析方法探讨ST6GALNAC1在头颈部鳞状细胞癌（HNSCC）中的表达及其预后和免疫学价值。方法从TCGA数据库中获取HNSCC的转录组数据,使用R软件Limma包筛选糖基转移酶差异基因。通过UALCAN和HPA数据库对ST6GALNAC1进行表达分析。用UALCAN数据库分析ST6GALNAC1表达与不同临床特征的相关性。通过GEPIA2可视化网站进行生存分析。通过TIMER2.0数据库进行ST6GALNAC1表达与肿瘤相关成纤维细胞的相关性分析。使用R软件包IOBR计算免疫浸润细胞评分,用Sangerbox工具对免疫检查点基因和HLA基因的表达差异进行可视化。通过STRING、GEPIA2和Sangerbox工具进行ST6GALNAC1相关基因的富集分析。利用WB和q-PCR检测人舌鳞癌细胞系Cal27的ST6GALNAC1表达水平。结果从TCGA数据库中筛选出HNSCC糖基转移酶差异基因ST6GALNAC1。在HNSCC中,ST6GALNAC1表达显著下调（P<0.05）。ST6GALNAC1表达与HNSCC患者的肿瘤分级、年龄、淋巴结转移状况存在相关关系（P<0.05）。ST6GALNAC1低表达组患者的总体生存期（OS）和无进展生存期（DFS）显著缩短（P<0.05）。ST6GALNAC1表达与肿瘤组织的免疫细胞浸润、免疫检查点基因和HLA基因的表达呈负相关性。GO和KEGG分析显示ST6GALNAC1相关基因主要参与糖蛋白的生物合成过程。实验结果显示,Cal27细胞的ST6GALNAC1蛋白和mRNA表达水平下降。结论 ST6GALNAC1在HNSCC中表达下调,与HNSCC患者预后不良、肿瘤微环境免疫细胞浸润相关。ST6GALNAC1在Cal27细胞中表达下调。ST6GALNAC1有望成为新的HNSCC治疗靶点。

关键词: 糖基转移酶, 头颈部鳞状细胞癌, 预后, 免疫浸润, 生物信息学

Abstract: Objective To investigate the expression of ST6GALNAC1 and its prognostic and immunological value in HNSCC by bioinformatics analysis. Methods The transcriptome data of HNSCC were obtained from TCGA database and an R package Limma was used to screen abnormally expressed glycosyltransferase genes. UALCAN database was leveraged to investigate the correlation between ST6GALNAC1 expression levels and distinct clinical signatures. GEPIA2 website was used to conduct survival analysis. The correlation between ST6GALNAC1 expression levels and tumor-associated fibroblasts was explored by harnessing TIMER2.0 database. The R package IOBR was exploited to calculate the score of the immune infiltrating cells, and the Sangerbox tool was utilized to visualize the disparities in the expression levels of the checkpoint and HLA genes. ST6GALNAC1-related genes were enriched by STRING, GEPIA2, and Sangerbox. The WB and qRT-PCR were adopted to detect the expression of ST6GALNAC1.Results A glycosyltransferase ST6GALNAC1 was found significantly downregulated in HNSCC and its expression levels were associated with tumor clinical pathology grade, age, and lymph node metastasis of HNSCC patients （P<0.05）. Patients with low expression of ST6GALNAC1 have substantially shorter overall survival（OS）and progression-free survival（DFS）（P<0.05）. The ST6GALNAC1 expression was negatively correlated with immune cell infiltration in tumor tissue, expression of immune checkpoint genes and HLA genes. GO and KEGG analysis revealed that ST6GALNAC1 genes were mainly involved in the biosynthesis of glycoproteins. The experiment results showed us the decreased expression of ST6GALNAC1 in Cal27 cells. Conclusion Sialyltransferase ST6GALNAC1 was down-regulated in HNSCC, which may be associated with inferior outcomes and immune infiltration of HNSCC patients. The expression of ST6GALNAC1 was down-regulated in Cal27 cells. ST6GALNAC1 may be a novel therapeutic target for HNSCC.

Key words: glycosyltransferase, head and neck squamous cell carcinoma, prognosis, immune infiltration, bioinformatic analysis

中图分类号:

R739.6

吴康秀, 黎志国, 刘穗萍, 苏鸿君, 熊敏敏. 唾液酸转移酶ST6GALNAC1在头颈部鳞状细胞癌中的表达及其预后和免疫学价值[J]. 岭南现代临床外科, 2023, 23(02): 152-161.

WU Kang-xiu, LI Zhi-guo, LIU Sui-ping, SU Hong-jun, XIONG Min-min. Prognostic and immunological role of sialyltransferase ST6GALNAC1 in head and neck squamous cell carcinoma[J]. Lingnan Modern Clinics In Surgery, 2023, 23(02): 152-161.

参考文献

[1] Leemans CR, Braakhuis BJ, Brakenhoff RH.The molecular biology of head and neck cancer[J]. Nat Rev Cancer, 2011, 11(1): 9-22.
[2] Chikuie N, Urabe Y, Ueda T, et al.Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma[J]. Sci Rep, 2022, 12(1): 9316.
[3] Mereiter S, Balmaña M, Campos D, et al.Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?[J]. Cancer Cell, 2019, 36(1): 6-16.
[4] Abbott KL, Nairn AV, Hall EM, et al.Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer[J]. Proteomics, 2008, 8(16): 3210-3220.
[5] Bennett EP, Mandel U, Clausen H, et al.Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family[J]. Glycobiology, 2012, 22(6): 736-756.
[6] Marcos NT, Pinho S, Grandela C, et al.Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen[J]. Cancer Res, 2004, 64(19): 7050-7057.
[7] Nguyen AT, Chia J, Ros M, et al. Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth,Metastasis [J]. Cancer Cell, 2017, 32(5): 639-653.e636.
[8] Wang Y, Ju T, Ding X, et al.Cosmc is an essential chaperone for correct protein O-glycosylation[J]. Proc Natl Acad Sci U S A, 2010, 107(20): 9228-9233.
[9] Bos PD, Zhang XH, Nadal C, et al.Genes that mediate breast cancer metastasis to the brain[J]. Nature, 2009, 459(7249): 1005-1009.
[10] Murugaesu N, Iravani M, van Weverwijk A, et al. An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor[J]. Cancer Discov, 2014, 4(3): 304-317.
[11] Munkley J.The Role of Sialyl-Tn in Cancer[J]. Int J Mol Sci, 2016, 17(3): 275.
[12] Carrascal MA, Severino PF, Guadalupe Cabral M, et al.Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells[J]. Mol Oncol, 2014, 8(3): 753-765.
[13] Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H.Global view of human protein glycosylation pathways and functions[J]. Nat Rev Mol Cell Biol, 2020, 21(12): 729-749.
[14] Chandrashekar DS, Karthikeyan SK, Korla PK, et al.UALCAN: An update to the integrated cancer data analysis platform[J]. Neoplasia, 2022, 25: 18-27.
[15] Colwill K, Gräslund S.A roadmap to generate renewable protein binders to the human proteome[J]. Nat Methods, 2011, 8(7): 551-558.
[16] Tang Z, Kang B, Li C, et al.GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): W556-w560.
[17] Li T, Fu J, Zeng Z, et al.TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-w514.
[18] Szklarczyk D, Gable AL, Nastou KC, et al.The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J]. Nucleic Acids Res, 2021, 49(D1): D605-d612.
[19] Wang WY, Cao YX, Zhou X, et al.Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway[J]. Cancer Cell Int, 2019, 19: 86.
[20] Iwaya T, Sawada G, Amano S, et al.Downregulation of ST6GALNAC1 is associated with esophageal squamous cell carcinoma development[J]. Int J Oncol, 2017, 50(2): 441-447.
[21] Kvorjak M, Ahmed Y, Miller ML, et al.Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer[J]. Cancer Immunol Res, 2020, 8(2): 167-178.
[22] Munkley J.Glycosylation is a global target for androgen control in prostate cancer cells[J]. Endocr Relat Cancer, 2017, 24(3): R49-r64.
[23] Yao Y, Kim G, Shafer S, et al. Mucus sialylation determines intestinal host-commensal homeostasis [J]. Cell, 2022, 185(7): 1172-1188. e1128.
[24] Maignien C, Santulli P, Chouzenoux S, et al.Reduced α-2,6 sialylation regulates cell migration in endometriosis[J]. Hum Reprod, 2019, 34(3): 479-490.
[25] Ozaki H, Matsuzaki H, Ando H, et al.Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model[J]. Clin Exp Metastasis, 2012, 29(3): 229-238.
[26] Jabeen S, Zucknick M, Nome M, et al.Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab[J]. Oncoimmunology, 2018, 7(11): e1457598.
[27] Chen X, Song E.Turning foes to friends: targeting cancer-associated fibroblasts[J]. Nat Rev Drug Discov, 2019, 18(2): 99-115.
[28] Curtis M, Kenny HA, Ashcroft B, et al. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis [J]. Cell Metab, 2019, 29(1): 141-155.e149.
[29] Miao L, Liu Q, Lin CM, et al.Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors[J]. Cancer Res, 2017, 77(3): 719-731.
[30] Galon J, Costes A, Sanchez-Cabo F, et al.Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313(5795): 1960-1964.
[31] Swann JB, Smyth MJ.Immune surveillance of tumors[J]. J Clin Invest, 2007, 117(5): 1137-1146.
[32] Roberts SJ, Ng BY, Filler RB, et al.Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis[J]. Proc Natl Acad Sci U S A, 2007, 104(16): 6770-6775.
[33] Hanada T, Kobayashi T, Chinen T, et al.IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice[J]. J Exp Med, 2006, 203(6): 1391-1397.
[34] DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages[J]. Cancer Cell, 2009, 16(2): 91-102.
[35] Langowski JL, Zhang X, Wu L, et al.IL-23 promotes tumour incidence and growth[J]. Nature, 2006, 442(7101): 461-465.
[36] Condeelis J, Pollard JW.Macrophages: obligate partners for tumor cell migration, invasion, and metastasis[J]. Cell, 2006, 124(2): 263-266.
[37] Murdoch C, Muthana M, Coffelt SB, Lewis CE.The role of myeloid cells in the promotion of tumour angiogenesis[J]. Nat Rev Cancer, 2008, 8(8): 618-631.
[38] Gallimore AM, Simon AK.Positive and negative influences of regulatory T cells on tumour immunity[J]. Oncogene, 2008, 27(45): 5886-5893.
[39] Hanahan D, Coussens LM.Accessories to the crime: functions of cells recruited to the tumor microenvironment[J]. Cancer Cell, 2012, 21(3): 309-322.
[40] Reticker-Flynn NE, Bhatia SN.Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche[J]. Cancer Discov, 2015, 5(2): 168-181.
[41] Schnaar RL, Gerardy-Schahn R, Hildebrandt H.Sialic Acids in the Brain: Gangliosides and Polysialic Acid in Nervous System Development, Stability, Disease, and Regeneration[J]. Physiological Reviews, 2014, 94(2): 461-518.